3 research outputs found
ASSESSING THE EFFICACY OF INVISIBLEWATERMARKS IN AI-GENERATED MEDICAL
No description supplie
High-performance hazardous aerogel/liquid barriers from fluffy, antibacterial superhydrophobic nanofiber membranes
Fibrous membranes have been regarded as one of the most effective barriers against hazardous matters, e.g., pathogen, airborne particulates, and liquids. However, developing multi-functional membranes with high air filtration performances, liquid barrier properties, and antibacterial activities remains challenging. Herein, a robust nanofibrous membrane with fluffy structure has been developed through a facile one-step electrospinning process. Under the synergistic effect of polyetherimide (PEI) nanofibers, low surface energy fluorinated alkyl silane (FAS), and fluorinated ZIF67 nanoparticles, the resultant PEI/FAS/F-ZIF67 composite nanofiber membrane shows superhydrophobicity with WCA of 155° and antibacterial activity with efficiency of over 99 %. The addition of FAS renders the membrane a fluffy fibrous structure, which further enhances the filtration performances with a filtration efficiency of 99.99 % and a low pressure drop of 125 Pa. Owing to the superhydrophobicity, the membrane also shows excellent liquid repellent properties with hydrostatic pressures of 60.6 kPa and 14.0 kPa to water and blood, respectively. Furthermore, benefiting from the excellent thermal stability of PEI, the composite membrane can well maintain its filtration performances at high temperature of 200 ℃. Overall, the proposed PEI/FAS/F-ZIF67 nanofiber membrane demonstrates high potential to be widely applied for air purification and medical protection applications
Maintenance of antiangiogenic and antitumor effects by orally active low-dose capecitabine for long-term cancer therapy.
Long-term uninterrupted therapy is essential for maximizing clinical benefits of antiangiogenic drugs (AADs) in cancer patients. Unfortunately, nearly all clinically available AADs are delivered to cancer patients using disrupted regimens. We aim to develop lifetime, nontoxic, effective, orally active, and low-cost antiangiogenic and antitumor drugs for treatment of cancer patients. Here we report our findings of long-term maintenance therapy with orally active, nontoxic, low cost antiangiogenic chemotherapeutics for effective cancer treatment. In a sequential treatment regimen, robust antiangiogenic effects in tumors were achieved with an anti-VEGF drug, followed by a low-dose chemotherapy. The nontoxic, low dose of the orally active prodrug capecitabine was able to sustain the anti-VEGF-induced vessel regression for long periods. In another experimental setting, maintenance of low-dose capecitabine produced greater antiangiogenic and antitumor effects after AAD plus chemotherapy. No obvious adverse effects were developed after more than 2-mo of consecutive treatment with a low dose of capecitabine. Together, our findings provide a rationalized concept of effective cancer therapy by long-term maintenance of AAD-triggered antiangiogenic effects with orally active, nontoxic, low-cost, clinically available chemotherapeutics